Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.16M Sell
9,740
-166,817
-94% -$77M ﹤0.01% 2116
2026
Q1
$84.8M Buy
176,557
+119,176
+208% +$61M 0.07% 320
2025
Q4
$32.2M Sell
57,381
-27,988
-33% -$15.9M 0.05% 506
2025
Q3
$43.9M Sell
85,369
-181,381
-68% -$79.2M 0.07% 360
2025
Q2
$83.7M Buy
266,750
+31,845
+14% +$9.56M 0.15% 175
2025
Q1
$71.6M Buy
234,905
+80,400
+52% +$27M 0.15% 160
2024
Q4
$51.3M Buy
154,505
+8,476
+6% +$2.87M 0.11% 223
2024
Q3
$48.7M Buy
146,029
+22,232
+18% +$8.45M 0.11% 228
2024
Q2
$51M Buy
123,797
+46,297
+60% +$18.3M 0.12% 205
2024
Q1
$31.3M Sell
77,500
-38,772
-33% -$13.6M 0.07% 317
2023
Q4
$35.6M Sell
116,272
-22,339
-16% -$6.03M 0.08% 289
2023
Q3
$33.6M Buy
138,611
+70,469
+103% +$18M 0.09% 265
2023
Q2
$16.4M Buy
68,142
+908
+1% +$189K 0.04% 466
2023
Q1
$12.6M Buy
67,234
+51,080
+316% +$10.6M 0.04% 505
2022
Q4
$3.43M Buy
+16,154
New +$3.23M 0.01% 1047
2022
Q2
Sell
-1,600
Closed -$262K 2778
2022
Q1
$262K Sell
1,600
-31,408
-95% -$5.18M ﹤0.01% 2261
2021
Q4
$7.18M Buy
33,008
+3,408
+12% +$714K 0.02% 984
2021
Q3
$5.6M Sell
29,600
-7,119
-19% -$1.3M 0.01% 1150
2021
Q2
$6.49M Buy
+36,719
New +$6.34M 0.01% 1037
2020
Q4
Sell
-20,911
Closed -$2.34M 3587
2020
Q3
$2.34M Buy
+20,911
New +$2.42M 0.01% 1201
2019
Q1
Sell
-194,301
Closed -$10.3M 3303
2018
Q4
$10.3M Sell
194,301
-283,788
-59% -$15.6M 0.04% 539
2018
Q3
$28.6M Buy
478,089
+158,918
+50% +$8.69M 0.08% 329
2018
Q2
$13.7M Buy
319,171
+196,841
+161% +$7.95M 0.04% 541
2018
Q1
$4.27M Sell
122,330
-79,313
-39% -$2.9M 0.01% 1046
2017
Q4
$7.31M Buy
201,643
+167,165
+485% +$5.86M 0.02% 726
2017
Q3
$1.1M Buy
+34,478
New +$1.05M ﹤0.01% 1674
2016
Q4
Sell
-34,479
Closed -$1.03M 3353
2016
Q3
$1.03M Buy
+34,479
New +$1.01M ﹤0.01% 1942

Other funds holding MEDP

John Overdeck's MEDP Position: Q2 2026 in Review

John Overdeck reduced its Medpace (MEDP) stake by 94% in Q2 2026, selling an estimated $77M and leaving 9,740 shares worth $5.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2116.

John Overdeck first reported a position in MEDP in Q3 2016 and has held it in 27 quarters since. The position peaked at $84.8M in Q1 2026. 693 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.

  • John Overdeck held 9,740 shares of Medpace worth $5.16M as of Q2 2026.
  • John Overdeck sold 166,817 Medpace shares in Q2 2026, an estimated $77M.
  • Medpace made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2116 holding.
  • John Overdeck first reported a position in Medpace in Q3 2016 and has held it in 27 quarters since.
  • John Overdeck's Medpace position peaked at $84.8M in Q1 2026.
  • 693 funds tracked by Wall St. Rank held Medpace as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.